Health • Verified Dispatch

Universal mRNA Antiviral Platform Enters Phase III Multicenter Clinical Trials

Researchers target conserved viral proteins to provide broad-spectrum immunity against seasonal and emerging respiratory strains.

facfltd
Bureau Correspondent
Published

Immunologists across fourteen university medical centers have begun enrolling volunteers for the largest broad-spectrum respiratory vaccine trial in history.

Share: